Alan Morrison joined MSD in mid-2015. As a key member of the Global Regulatory Affairs and Clinical Safety global function, Alan leads a global ex-US regulatory organisation spanning Europe, Middle East and Africa, Latin America and Asia Pacific regional hubs and almost 60 local subsidiary offices, as well as for Merck Canada, plus supporting US-based cross-regional international teams. His leadership covers a global team of 750 people operating across multiple therapeutic areas including anti-invectives, oncology, diabetes, cardiology, neuroscience and vaccines, and multiple modalities.
Alan is also a member of key cross-functional, strategic management committees with governance responsibility for the overall strategy and performance of MSD regional businesses in both established and growth markets/regions.
Prior to MSD, Alan was from 2004 Vice-President of International Regulatory Affairs and Safety at Amgen managing an organisation of 400 people both in the UK and across more than 30 local affiliate offices worldwide, as well as being part of the Global Regulatory Affairs and Safety (GRAAS) global functional leadership. Alan was also key member of Amgen's International Management Committees for Europe and emerging markets.
Prior to Amgen, Alan previously held a number of regulatory affairs and safety executive positions at a number of companies including Baxter Bioscience.
Alan is chair’s EFPIA’s Regulatory Strategy Committee and is a Member of its Innovation Board. Previously Alan was also chair of EFPIA’s Brexit taskforce and a member of the Mayor of London’s Brexit Advisory Panel.